Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(2):104-106; doi:10.1093/jnci/91.2.104
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Darzynkiewicz, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Darzynkiewicz, Z.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 2, 104-106, January 20, 1999
© 1999 Oxford University Press

EDITORIALS

The Butler Did It: Search for Killer(s) of Kaposi's Sarcoma Cells in Preparations of Human Chorionic Gonadotropin

Zbigniew Darzynkiewicz

Correspondence to: Zbigniew Darzynkiewicz, M.D., Brander Cancer Research Institute, New York Medical College, 19 Bradhurst Ave., Hawthorne, NY 10532.

Since its original description more than a century ago, Kaposi's sarcoma (KS) was considered to be a rare dermatologic condition, and it attracted only limited attention. The association with immune deficiency, first noticed in patients who had undergone renal transplantation, started to generate more interest in this disease. The turning point, however, was the finding of a relationship between KS and acquired immunodeficiency syndrome (AIDS). KS is now recognized as the most prominent tumor of patients with AIDS, particularly common (>30%) among homosexual men. It is not surprising, therefore, that the interest in its etiology, pathogenesis, and therapy is widespread.

Unfortunately, the treatment options for KS are limited. Radiotherapy or chemotherapy as well as the administration of interferon alfa have little impact on the disease. Furthermore, these treatments are toxic, especially when used in combination with antiviral therapies. It is not surprising, therefore, that the finding that sera from pregnant . . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Mol. Cell. ProteomicsHome page
S. Malatos, H. Neubert, A. T. Kicman, and R. K. Iles
Identification of Placental Transforming Growth Factor-{beta} and Bikunin Metabolites as Contaminants of Pharmaceutical Human Chorionic Gonadotrophin Preparations by Proteomic Techniques
Mol. Cell. Proteomics, July 1, 2005; 4(7): 984 - 992.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. A. Butler and R. K. Iles
Ectopic Human Chorionic Gonadotropin {beta} Secretion by Epithelial Tumors and Human Chorionic Gonadotropin {beta}-Induced Apoptosis in Kaposi's Sarcoma: Is There a Connection?
Clin. Cancer Res., October 15, 2003; 9(13): 4666 - 4673.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
N. W. Bengtson and D. I. H. Linzer
Inhibition of Tumor Growth by the Antiangiogenic Placental Hormone, Proliferin-Related Protein
Mol. Endocrinol., December 1, 2000; 14(12): 1934 - 1943.
[Abstract] [Full Text]

Home page
 J Natl Cancer Inst MonogrHome page
A. M. Cattelan, M. L. Calabro, P. Gasperini, S. M. L. Aversa, M. Zanchetta, F. Meneghetti, A. De Rossi, and L. Chieco-Bianchi
Acquired Immunodeficiency Syndrome-Related Kaposi's Sarcoma Regression After Highly Active Antiretroviral Therapy: Biologic Correlates of Clinical Outcome
J Natl Cancer Inst Monographs, December 1, 2000; 2000(28): 44 - 49.
[Abstract] [Full Text] [PDF]